超越lecanemab:检查阿尔茨海默氏症治疗药物的第三阶段潜力
Hitoshi Osaka1, Keiichiro Nishida1, Tetsufumi Kanazawa1
1Department of Neuropsychiatry Osaka Medical and Pharmaceutical University Takatsuki Osaka Japan.
PCN reports : psychiatry and clinical neurosciences
|June 13, 2024
概括
创新的阿尔茨海默氏症痴呆症疗法正在进步,在后期试验中,新的药物向粉样蛋白和蛋白. 最近的FDA批准表明了进展,为改善患者治疗结果提供了希望.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 已建立的阿尔茨海默氏症痴呆症治疗向乙胆和NMDA受体.
- 人口老龄化推动了对新型治疗干预措施的需求.
- 最近FDA对阿杜卡努马布和莱卡努马布的批准突出显示了不断变化的治疗场景.
研究的目的:
- 审查阿尔茨海默氏症痴呆症治疗干预措施的发展.
- 详细介绍三期临床试验中的七种主要药物.
- 检查新的阿尔茨海默氏症治疗的作用机制和监管状况.
主要方法:
- 文献审查侧重于III期临床试验.
- 针对粉样蛋白去除,蛋白缓解和疾病修饰的药物的分析.
- 检查美国和日本的临床试验特点.
主要成果:
- 七种主要药物正在III期试验中,具有不同的机制,包括粉样蛋白去除 (donanemab) 和陶减轻 (E2814).
- 药物重新定位候选物 (塞马格卢提德,GV1001) 和修饰疾病的小分子 (氏,氨酸,马西替尼布) 正在研究中.
- 甘特内卢马布和索拉内卢马布在III期试验中失败,因此被排除在本次审查之外.
结论:
- 新的阿尔茨海默氏症痴呆症疗法显示出希望,有几种药物处于后期发展阶段.
- 目前正在进行的研究重点是超越传统受体点的新机制.
- 未来的批准可能为痴呆症患者提供显著的治疗益处.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.8K
相关概念视频
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120